What's trending, explained.
What's trending, explained.
A new study published in The Lancet Psychiatry reports that glucagon-like peptide-1 receptor agonists — the class of drugs that includes semaglutide, liraglutide, and tirzepatide, best known as diabetes and weight-loss medications — were associated with lower rates of psychiatric hospitalization and emergency department visits in people living with both schizophrenia and type 2 diabetes.
Researchers from Australia's Deakin University and the University of Queensland analyzed US health records for more than 70,000 adults with both schizophrenia and type 2 diabetes who received treatment between January 2018 and October 2026. Some had been prescribed a GLP-1; others had been prescribed a different, newer type of diabetes medication (a DPP-4 inhibitor or an SGLT2 inhibitor); and some had not been prescribed any of these treatments.
The differences were striking. People taking GLP-1s were 24 percent less likely to need psychiatric hospital admission than those not taking any of these diabetes medications — and they also compared favorably against the other diabetes drugs: 18 percent less likely than those taking DPP-4 inhibitors and 17 percent less likely than those taking SGLT2 inhibitors. Psychiatric emergency department visits showed a similar pattern: 29 percent lower than those on none of the compared medications. The association was observed with semaglutide, liraglutide, and tirzepatide, but not with dulaglutide. It was strongest among men and adults under 55.
The link between schizophrenia and diabetes is clinical, not coincidental. People with schizophrenia have a two- to five-fold higher risk of developing type 2 diabetes than the general population — and many antipsychotic medications are known to cause weight gain and metabolic changes as side effects. Yet whether GLP-1s affect the mental health of people with schizophrenia had remained uncertain until now.
The most intriguing finding is that weight loss does not fully explain the effect. The association was strongest among people who lost weight, but it was also present — to a lesser extent — among those whose weight stayed stable or even increased. That suggests weight-independent mechanisms may be involved. One of the study authors hypothesized that better metabolic health might support "psychiatric stability," and separate research presented at the ERS Congress has pointed to possible anti-inflammatory and neuroprotective effects of GLP-1s in bipolar disorder.
The study is observational, which is an important caveat. It shows a strong association, not proof that the drugs caused the improvement — healthier patients may differ from sicker ones in ways the records cannot fully capture. The authors stress the finding is preliminary and requires confirmation in randomized trials. And this is not treatment advice: anyone with schizophrenia should consider discussing medication options with a healthcare professional rather than acting on headlines.
The finding adds schizophrenia to a growing list of conditions that GLP-1s may benefit beyond weight and blood sugar — researchers have already reported links to fewer asthma exacerbations and slower cognitive decline. Expect the result to trigger new grant proposals and, more importantly, the randomized controlled trials needed to test whether the effect is real and safe in this population.
For now, the practical significance is mostly for the prescribers who already treat the large overlap population: clinicians managing a patient with schizophrenia and diabetes may weigh this association when choosing among diabetes medications. The fuller answer — mechanism, magnitude, and which patients benefit most — will take years of trials to arrive.